Slowdown in acute gastro portfolio
Domestic growth was impacted by slowdown in acute gastro portfolio, which could persist and drag overall domestic growth.
JBCHEPHARM / Q3-FY26 / risks
Keep the risk register visible.
JB Chemicals & Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Merger with Torrent delayed or not completed
Merger closure expected in Q4 FY26, but management was evasive on timeline and synergies, indicating potential delays.
High base effect in CDMO business
CDMO segment remained flat due to high base in Q3 FY25; growth may be lumpy going forward.